Assessment Run GATA3

Similar documents
Sal-like protein 4 (SALL4)

SMH (Myosin, smooth muscle heavy chain)

Estrogen receptor (ER)

Carcinoembryonic antigen (CEA)

Thyroid transcription factor-1 (TTF1) Assessment run

Lung Anaplastic Lymphoma Kinase (lu-alk)

Assessment Run NKX3.1 (NKX3.1)

Assessment Run

Estrogen receptor (ER)

Assessment Run CK19

Estrogen receptor (ER)

Assessment Run B HER2 IHC

Assessment Run B HER-2 IHC. HER-2/chr17 ratio**

Cytokeratin 19 (CK19)

Epithelial cell-cell adhesion molecule (Ep-CAM)

Assessment Run B HER2 IHC

Assessment Run C1 2017

Assessment Run C3 2018

HER2 ISH (BRISH or FISH)

Optimization of antibodies, selection, protocols and controls Breast tumours

Breast cancer: Antibody selection, protocol optimzation controls and EQA

Assessment Run B HER-2

IHC Stainer platforms. Overview, pros and cons

External Quality Assessment of melanocytic marker analyses NordiQC experience

Quality Assurance in Immunohistochemistry: Experiences from NordiQC

10 years of NordiQC Why are 30% of labs still getting it wrong?

NordiQC - update

Nordic Immunohistochemical Quality Control

Product Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue

Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital

Assessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver

NordiQC External Quality Assurance in Immunohistochemistry

External Quality Assessment of Breast Marker Analysis. NordiQC data

Immunohistochemical principles The technical test approach. Pre-analytical parametres

Single and Multiplex Immunohistochemistry

The impact of proficiency testing on lab immunoassays

Supplementary Online Content

The unknown primary tumour: IHC classification part I, the primary panel - Antibody selection, protocol optimization, controls and EQA

Image analysis in IHC overview, considerations and applications

HPV/p16 Analyte Control

HistoCyte Laboratories Ltd

Immunocytochemistry. Run 119/48. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

IDH1 R132H/ATRX Immunohistochemical validation

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part I)

Milestones in Her 2 Testing

Diagnostic IHC in lung and pleura pathology

Product Introduction

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

Supplemental figure 1. PDGFRα is expressed dominantly by stromal cells surrounding mammary ducts and alveoli. A) IHC staining of PDGFRα in

PD-L1 Analyte Control DR

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part II)

Results you can trust

Immunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Immunotherapy in NSCLC Pathologist role

Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012

Classification of the unknown primary tumour: the primary IHC panel

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy

Immunocytochemistry. Run 113/42. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

The Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia

VENTANA PD-L1 (SP142) Assay

Anti-PD-L1 antibody [28-8] ab205921

Immunohistochemistry. Potential and challenges To be or not to be

Supplemental Data Table 1 Characteristics of the MHH BC cohort number percent cases histology IDBC ILBC others 6 3 pt status pt1

Supplementary Appendix

Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods

VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue

COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC

Immunocytochemistry. Run 120/49. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Thermo Scientific UltraVision Quanto for Immunohistochemistry The New Generation Micro-Polymer Detection System

Breast cancer diagnostic solutions Deliver diagnostic confidence

Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers

ONCO TEAM DIAGNOSTIC

Review of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo

Immunocytochemistry. Results - Summary Graphs - Pass Rates Best Methods - Selected Images. Run 100. Assessment Dates: 3 rd - 22 nd January 2013

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

The PAX8 gene is a member of the paired-box family of

NSCLC. Harmonization study 1. Lung cancer and other malignancies -PD-L1 assay, QuIP EQA

Molecular Probes Introducing 14 new probes

Immunocytochemistry. Run 106/35. Also In This Issue IN THIS ISSUE

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we

Optimal algorithm for HER2 testing

TITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1. Immunohistochemistry in Non-Small Cell Lung Carcinoma

Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies

Immunohistochemistry on Fluid Specimens: Technical Considerations

A National Quality Assurance program for breast immunohistochemistry: an Italian perspective

Bond Ready-to-Use Primary Antibody Progesterone Receptor (16)

Speaking to you. This statement by Dr. Rodney T. Miller, Director of

Patterns of E.cadherin and Estrogen receptor Expression in Histological Sections of Sudanese Patients with Breast Carcinoma

Quality Control/Quality Assurance in Diagnostic Immunohistochemistry

Novocastra Liquid Mouse Monoclonal Antibody CD71

Stromal CD10 immunohistochemical expression in urothelial carcinoma of urinary bladder and correlation with clinicopathological parameters

Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue

IHC Polymer. BioGenex Website. Presented for: Presented by: Date: BioGenex Tech Support 2016

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?

Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -

CC01 - Colon Cancer Tissue Microarray

Transcription:

Assessment Run 44 2015 GATA3 Material The slide to be stained for GATA3 comprised: 1. Tonsil 2. Kidney, 3. Urothelial carcinoma, 4. Breast ductal carcinoma, 5. Colon adenocarcinoma All tissues were fixed in 10% neutral buffered formalin. Criteria for assessing GATA3 staining as optimal included: An at least moderate, distinct nuclear staining reaction of virtually all epithelial cells in collecting ducts and podocytes in glomeruli in the kidney An at least weak nuclear staining reaction of the majority of T-cells in the T-zones in the tonsil and dispersed T-cells in all tissues A moderate to strong nuclear staining reaction of virtually all neoplastic cells in the breast ductal carcinoma An at least weak to moderate nuclear staining reaction of the majority of neoplastic cells in the urothelial carcinoma No staining reaction of neoplastic cells of the colon adenocarcinoma Participation Number of laboratories registered for GATA3, run 44 129 Number of laboratories returning slides 124 (96%) Results 124 laboratories participated in this assessment. Out of these, 89 (72%) laboratories achieved a sufficient mark (optimal or good). Table 1 summarizes the antibodies (Abs) used and assessment marks (see page 2). The most frequent causes of insufficient staining were: - Less successful primary antibody - Use of less sensitive detection systems - Too low concentration of the primary antibody - Insufficient HIER (too short efficient heating time) Performance history This was the first NordiQC assessment of GATA3. A pass rate of 72% was observed. Table 2. Proportion of sufficient results for GATA3 in the first NordiQC run performed Run 44 2015 Participants, n= 124 Sufficient results 72% Conclusion The was found to be a very robust and recommendable antibody clone for demonstration of GATA3. In concentrated format within a laboratory developed assay, optimal results could be obtained on all three main IHC platforms (Dako, Leica and Ventana) and in general a high pass rate was observed. Efficient HIER, preferable in an alkaline buffer, and careful calibration of the primary antibody were the most important prerequisites for optimal staining results. Corresponding RTU formats of the and especially the Ventana/Cell Marque system provided a high pass rate and proportion of optimal results. Normal kidney and tonsil are recommendable as positive and negative tissue controls for GATA3. Virtually all epithelial cells in collecting ducts and podocytes in glomeruli in the kidney must show a moderate to strong nuclear staining reaction, while an at least weak but distinct nuclear staining reaction of T-cells must be seen. No staining reaction of B-cells should be seen. Nordic Immunohistochemical Quality Control, GATA3 run 44 2015 Page 1 of 5

Table 1. Antibodies and assessment marks for GATA3, run 44 Concentrated antibodies n Vendor Optimal Good Borderline Poor 27 48 3 1 Biocare Cell Marque Immunologic Zeta Suff. 1 Suff. OPS 2 23 31 22 3 68% 69% mab clone HG3-31 6 Santa Cruz 0 0 0 6 0% - Polyclonal 1 Acris 0 0 0 1 - - Ready-To-Use antibodies 760-4897 MAD000632-QD 390M-18 PM405AA MAB-0695 ZM-0498 20 Ventana/Cell Marque 13 7 0 0 100% 100% 3 Master Diagnostica 1 1 1 0 - - 9 Cell Marque 2 7 0 0 100% 100% 3 BioCare 1 2 0 0 - - 1 Maixin 0 1 0 0 - - 1 Zeta 0 0 1 0 - - mab clone HG3-31 1 Santa Cruz 0 0 0 1 - - Total 124 40 49 24 11 - Proportion 30% 41% 20% 9% 72% 1) Proportion of sufficient stains (optimal or good) 2) Proportion of sufficient stains with optimal protocol settings only, see below. Detailed analysis of GATA3, Run 44 The following protocol parameters were central to obtain optimal staining: Concentrated antibodies : The protocols with an optimal result were all based on heat induced epitope retrieval (HIER) using Target Retrieval Solution (TRS) ph 9 (3-in-1) (Dako) (3/19), TRS ph 6.1 (Dako) (1/6) Bond Epitope Retrieval Solution 2 (Bond, Leica) (1/7) or Cell Conditioning 1 (BenchMark, Ventana)(17/41) as retrieval buffer. The mab was typically diluted in the range of 1:70 1:500 depending on the total sensitivity of the protocol employed. Using these protocol settings 48 of 70 (69 %) laboratories produced a sufficient staining (optimal or good). * (number of optimal results/number of laboratories using this buffer) Table 3. Proportion of optimal results for GATA3 for the most commonly used antibody as concentrate on the 3 main IHC systems* Concentrated antibodies Dako Autostainer Link / Classic Ventana BenchMark XT / Ultra Leica Bond III / Max TRS ph 9.0 TRS ph 6.1 CC1 ph 8.5 CC2 ph 6.0 ER2 ph 9.0 ER1 ph 6.0 mab clone L50-823 3/16** (19%) 1/6 (17%) 18/36 (50%) - 1/7 (14%) 0/1 * Antibody concentration applied as listed above, HIER buffers and detection kits used as provided by the vendors of the respective systems. ** (number of optimal results/number of laboratories using this buffer) Ready-To-Use antibodies and corresponding systems, product no. 760-4897, Ventana, BenchMark XT, ULTRA: Protocols with optimal results were typically based on HIER using Cell Conditioning 1 (efficient heating time 24-64 min.), 16-32 min. incubation of the primary Ab and iview (760-091), UltraView (760-500) or OptiView (760-700) as detection system. Using these protocol settings 20 of 20 (100%) laboratories produced a sufficient staining result. Comments In this first NordiQC assessment for GATA3, the prevalent feature of an insufficient result was a too weak or completely false negative staining reaction of the cells expected to be demonstrated. This pattern was seen in 94% of the insufficient results (33 of 35 laboratories). A too weak staining result was characterized Nordic Immunohistochemical Quality Control, GATA3 run 44 2015 Page 2 of 5

by a reduced staining reaction both in regard to the intensity and proportion of cells expected to be demonstrated. The remaining insufficient results were caused by a poor signal-to-noise ratio compromising the interpretation. Virtually all laboratories were able to demonstrate GATA3 in high-level antigen expressing cells, such as neoplastic cells of the breast ductal carcinoma and epithelial cells of the renal collecting ducts. However, demonstration of GATA3 in low-level antigen expressing cells as normal T-cells in the tonsil and neoplastic cells of urothelial carcinoma was more challenging and required optimally calibrated protocols. Optimal staining results could only be obtained with the. Used as concentrated format within a laboratory developed (LD) assay, optimal results could be provided on all three main IHC platforms from Dako, Leica and Ventana (see table 3). For optimal performance of, efficient HIER in an alkaline buffer in combination with a careful calibration of the primary Ab seem to be the most critical parameters. Both 2- and 3-step polymer and multimer based detection systems could be used to obtain an optimal result. The mab clone HG3-31, Santa Cruz showed a less successful performance. The Ab was used by 6 laboratories as a concentrate and despite similar protocol settings, e.g. HIER, detection systems etc., as for the were applied, all protocols produced insufficient staining results (borderline or poor) as shown in table 1.The main feature of these 6 insufficient protocols was too weak or false negative staining reaction. Corresponding Ready-To-Use (RTU) formats for provided higher pass rates and proportion of optimal results compared to LD assays. Especially the Ventana RTU system based on the was successful as a pass rate of 100% was seen. Optimal results could both be obtained when using the official protocol recommendations given by Ventana and by laboratory modified protocol settings, typically adjusting HIER time, incubation time of the primary Ab and/or choice of detection system. Controls Kidney and tonsil is recommended as positive and negative tissue controls for GATA3. In kidney, moderate to strong nuclear staining reaction in virtually all epithelial cells lining the collecting ducts and podocytes in glomeruli must be seen. In tonsil the vast majority of T-cells in the T-zones must show an at least weak but distinct nuclear staining reaction. No staining of B-cells should be seen (dispersed intra-germinal T- cells will be identified). Fig. 1a (x200) Optimal GATA3 staining of the kidney using the mab clone L50-823 as a concentrate, optimally calibrated with HIER in an alkaline buffer (CC1 ph 8.5, Ventana) and a 3-step multimer based detection system (UltraView, Ventana). A moderate to strong nuclear staining reaction is seen in the majority of epithelial cells lining the collecting ducts and in podocytes in glomeruli. Same protocol used in Figs. 1a - 4a. Fig. 1b (x200) Insufficient GATA3 staining of the kidney using the mab clone L50-823. The protocol provided an overall reduced sensitivity primarily caused by a too low concentration of the primary Ab. The intensity and proportion of cells demonstrated is reduced compared to the level expected - same field as in Fig. 1a. Also compare with Figs. 2b - 4b, same protocol. Nordic Immunohistochemical Quality Control, GATA3 run 44 2015 Page 3 of 5

Fig. 2a (x200) Optimal GATA3 staining of the tonsil using same protocol as in Fig. 1a. T-cells primarily located in the T-zones but also within the germinal center show a weak to moderate, distinct nuclear staining reaction. No background staining is seen. Fig. 2b (x200) Insufficient GATA3 staining of the tonsil using same protocol as in Fig. 1b same field as in Fig. 2a. Virtually no staining reaction of T-cells is seen. Also compare with Figs. 3b and 4b, same protocol. Fig. 3a (x200) Optimal GATA3 staining of the breast ductal carcinoma using same protocol as in Figs. 1a & 2a. Virtually all neoplastic cells show a moderate to strong nuclear staining reaction. No background staining is seen. Fig. 3b (x200) Staining of the breast ductal carcinoma using same protocol as in Figs. 1b & 2b same field as in Fig. 3a. The vast majority of neoplastic cells are demonstrated, whereas the intensity is reduced, compared to the level expected and seen in Fig. 3a. However compare with Figs. 4a and 4b. Nordic Immunohistochemical Quality Control, GATA3 run 44 2015 Page 4 of 5

Fig. 4a (x200) Optimal GATA3 staining of the urothelial carcinoma using same protocol as in Figs. 1a - 3a. The majority of neoplastic cells show a distinct, weak to moderate nuclear staining reaction. Fig. 4b (x200) Insufficient GATA3 staining of the urothelial carcinoma using same protocol as in Figs. 1b 3b same field as in Fig. 4a. Only a weak and equivocal nuclear staining reaction in dispersed neoplastic cells is observed. Fig. 5a (x200) Insufficient GATA3 staining of the kidney using a pab with HIER in an alkaline buffer (TRS ph 9, Dako) and a 2-step polymer based detection system (FLEX, Dako). A poor signal-to-noise ratio is seen due to an aberrant cytoplasmic staining reaction in combination with only a faint specific nuclear staining. Also compare with Fig. 5b, same protocol. Fig. 4b (x200) Insufficient GATA3 staining of the urothelial carcinoma using same protocol as in Fig. 5a based on a pab. A nuclear staining reaction in stromal cells is seen, while the neoplastic cells are false negative. JLL/SN/RR/LE/MV 24-6-2015 Nordic Immunohistochemical Quality Control, GATA3 run 44 2015 Page 5 of 5